FSTL1 sustains glioma stem cell stemness and promotes immunosuppressive macrophage polarization in glioblastoma
Cancer Letters · 2025-02 · 611 · 217400
DOI: 10.1016/j.canlet.2024.217400 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025-02. Verfasst von Fengqi Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; Department of Neurosurgery, Second Affiliate…. Hauptthemen laut MEDLINE: Follistatin-Related Proteins, Neoplastic Stem Cells, Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Priority Academic Program Development of Jiangsu Higher Education Institutions, National Natural Science Foundation of China.
Abstract (Originalsprache)
Tumor-associated macrophages (TAMs) within the tumor microenvironment (TME) play a crucial role in glioblastoma (GBM) progression by interacting with glioma stem cells (GSCs). These interactions lead to the polarization of TAMs toward an M2 phenotype, which, in turn, enhances the stem-like traits and malignant progression of GSCs. Our study shows that FSTL1, a protein released by GSCs, is significantly elevated in gliomas and linked to the progression of the disease. By suppressing FSTL1 in a mouse model, we observed reduced tumor growth and a decrease in M2 macrophages. In vitro studies show that FSTL1 from GSCs promotes M2 polarization and infiltration. Importantly, GSCs utilize autocrine FSTL1 to interact with TLR2, which inhibits the endocytosis-lysosomal degradation pathway mediated by EGFR, resulting in the activation of the PI3K-AKT signaling pathway that is critical for maintaining their self-renewal. These findings underscore the importance of FSTL1 in GSC maintenance and M2 macrophage polarization, suggesting that interventions targeting the FSTL1/TLR2 pathway could provide a novel therapeutic approach for GBM patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
- Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- State Key Laboratory Cultivation Base of Research, Prevention and Treatment for Oral Diseases, The Affiliated Stomatological Hospital of Nanjing Medical University, Nanjing, China.
- Department of Neurosurgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
- Department of Neurosurgery, The Affiliated Chuzhou Hospital of Anhui Medical University, The First People's Hospital of Chuzhou, Chuzhou, Anhui, China.
- Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. Electronic address: jijx@zju.edu.cn.
Förderung
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- National Natural Science Foundation of China
Zitieren
APA
Zhou, F., Tao, J., Gou, H., Liu, S., Yu, D., Zhang, J., Ji, J., Lin, N., & Wang, Y. (2025). FSTL1 sustains glioma stem cell stemness and promotes immunosuppressive macrophage polarization in glioblastoma. Cancer Letters, 611, 217400. https://doi.org/10.1016/j.canlet.2024.217400
Vancouver
Zhou F, Tao J, Gou H, Liu S, Yu D, Zhang J, et al. FSTL1 sustains glioma stem cell stemness and promotes immunosuppressive macrophage polarization in glioblastoma. Cancer Letters. 2025;611:217400. doi:10.1016/j.canlet.2024.217400
BibTeX
@article{Zhou2025,
author = {Zhou, Fengqi and Tao, Jincheng and Gou, Huiqing and Liu, Shuheng and Yu, Dong and Zhang, Junxia and Ji, Jianxiong and Lin, Ning and Wang, Yingyi},
title = {FSTL1 sustains glioma stem cell stemness and promotes immunosuppressive macrophage polarization in glioblastoma},
journal = {Cancer Letters},
year = {2025},
volume = {611},
pages = {217400},
doi = {10.1016/j.canlet.2024.217400}
}
EUVIMED